Loading stock data…
DRTS
$8.54+0.20 (+2.40%)
Market ClosedLast close May 1
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Tau Medical Ltd. in the Healthcare sector is trading at $8.54. The stock is currently near its 52-week high of $8.80, remaining 62.4% above its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why DRTS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.54
Potential Upside
5%
Whystock Fair Value$8.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technolog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$702.32M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-55.29%
Volume
Today's trading volume
907,568
Recent News
Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased
Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting what company leadership described as “real and meaningful activity” over the past few months and setting expectations for multiple data readouts later in 2026. The discussion
Alpha Tau price target raised to $12 from $9 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The approval in Japan further validates the Alpha DaRT platform and helps de-risk the clinical development in the U.S., the analyst tells investors.Claim 50% Off TipRanks Premi
New Strong Sell Stocks for January 27th
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
New Strong Sell Stocks for January 20th
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention
As the U.S. stock market surges on news of a trade deal with the UK, investors are keenly observing how such developments might influence various sectors, including smaller-cap stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points despite being considered a somewhat outdated term. By focusing on strong financials and solid fundamentals, these under-the-radar investments can present compelling...